Continuation of: http://studyfacts1.blogspot.com. Nearly 700 published studies conclude extensive physiological, reproductive, and neurological adverse soy phyto-toxic effects that are especially health threatening during fetal, infant, and child exposure:
Placental (fetal) transfer of soy toxicity, and again to child through breast milk:
Mol Med 2002, Nov;8(11):742-9 "Early exposure to genistein exerts long lasting effects on the endocrine and immune systems in rats" The W. Harry Feinstone Dept of Molecular Microbiology and Immunology Johns Hopkins. "These data illustrate that exposure to genistein during pregnancy and lactation exerts long-lasting effects on the endocrine and immune systems in adulthood. Whether exposure to phytoestrogens during early development affects responses to infections or autoimmune diseases, as well as cancers later in life requires investigation."
Soy-cause of brain disorders:
Toxicol Sci 2003 Apr:72(2): 296-300, Scallet AC et al, "Dietary exposure to genistein increases vasopressin but does not alter beta-endrophin in the rat hypothalamus" ascallet@nctr.fda.gov "Elevated vasopressin levels may be associated with fluid balance, altered blood pressure, and cardiovascular effects. These data are consistent with the known actions of estradiol and may serve to explain our findings in a previous study that estrogenic endocrine-disruptors such as genistein increased sodium preference in rats exposed through their diet."
(Note: Elevated vasopressin is also a reported cause of neurological disorders including autism).
Life Sci 2004 Jun 11;75(4):499-509 “Evidence for genistein mediated cytotoxicity and apoptosis in rat brain.” Medicinal Science Division, Korea Research Institute of Chemical Technology, South Korea. EJ Choi and BH Lee. “The effects of chronic treatment with high doses of genistein, a major isoflavone of soybeans and soy-based products, have yet to be determined and what is known remains controversial. Sprague-Dawley rats were given 2 or 20 mg/day genistein for four weeks. The high dose of genistein (20mg/day) significantly increase lactate dehyrogenase in rat brain tissue homogenates, whereas the low dose of genistein (2mg/day) decrease LDH. In addition, DNA fragmentation was detected in homogenates of brain tissue from rats receiving either dose of genistein. These results are consistent with those of in vitro studies indication that high concentrations of genistein caused cytotoxicity and DNA ladder formation in primary cultures of cortical neurons.”
Neurotoxicol Teratol 2002 Jan-Feb:24(1):47-54, Center for Behavioral Neuroscience, Emory University. antpw@emory.edu "Neurobehavioral actions of coumestrol and related isoflavonoids in rodents" PL Whitten et al “The lordotic response to estrogen was significantly reduced by 2 days of treatment of OVX adult females with an isoflavone diet providing 13 ppm genistein and 33 ppm daidzein. One week of treatment with the same isoflavone diet produced an effect opposite to that of estradiol in the PVN, increasing ERbeta mRNA expression above control levels. These investigations show that, in spite of their preferential affinity for ERbeta, isoflavonoids act through both ER(alpha) and ERbeta. Moreover, their neurobehavioral actions were antiestrogenic, either antagonizing or producing an action in opposition to that of estradiol. This work demonstrates that even small, physiologically relevant exposure levels can alter estrogen-dependent gene expression in the brain and complex behavior.”
2002 National Institutes of Health Clinical Center, “Phase 2A Study of Soy Isoflavones in the Treatment of Major Depression” NIH. “Genistein is a polyphenolic molecule and the active form of the soy isoflavone, genistin. It has both phytoestrogen and protein tyrosine kinase inhibiting properties. Since tyrosine phosphorylation is involved in central nervous system regulation of neurotransmission, inhibition by genistein may be a novel strategy to directly modulate synaptic activity….. Genistein increases dopamine and other monoamine activity, affects neurotrophic factor transcription….”
(Note: A decade ago the NIH quietly confesses the fact that soy phyto-estrogens and soy inhibition of tyrosine kinase interrupts brain systems without public disclosure. Each are proven as capable of causing adverse neurological effects during developmental exposure).
Soy Is A Highly Toxic Estrogenic Endocrine Disruptor :
Reprod Toxicol, 2001 Nov-Dec:15(6):647-63. KE Delclos et al, Division of Biochemical Toxicology, NCTR. bdelclos@nctr.fda.gov “Effects of dietary genistein exposure during development on male and female CD rats." Dietary genistein thus produced effects in multiple estrogen-sensitive tissues in males and females that are generally consistent with its estrogenic activity. These effects occurred within exposure ranges achievable in humans."
Toxicol Sci 2002, Mar;66(1):91-104 “Combined effects of dietary phytoestrogen and synthetic endocrine-active compound on reproductive development in Sprague-Dawley rats: genistein and methoxychlor” You L et al Centers for Health Research, Triangle Park, NC you@ciit.org “Humans and wildlife are frequently exposed to mixtures of endocrine active-compounds (EAC). The estrogenic responses to genistein and methoxychlor administrated together were apparently accumulative of the effects associated with each compound alone. Data from this study indicate that phytoestrogens are capable of altering the toxicological behaviors of other EDCs and the interactions of these compounds may involve complexities that are difficult to predict based on their in vitro steroid receptor reactivities.”
Toxicol Appl Pharmacol 2007 Oct 1;224(1):1-11 “Genistein geneotoxicity critical considerations of in vitro exposure dose” CB Klein and AA King. Nelson Institute of Environmental Medicine NY University. kleinc@env.med.nyu.edu “Although there is increasing popularity of dietary phytoestrogen supplementation and of vegetarian and vegan diets among adolescents and adults, concerns about potential detrimental or other genotoxic effects persist. In toxicology the well accepted principle of “the dose defines the poison” applies to many toxicants and can be invoked herein, to distinguish genotoxic versus potentially beneficial in vitro effects of natural dietary products such as genistein.”
Natl Toxicol Program (NTP) Tech Rep Ser 2008 Jan;(545):1-240 “Toxicology and carcinogenesis studies of genistein (Cas No. 446-72-0) in Sprague-Dawley rats (feed study).” U.S. Dept of Health and Human Services National Toxicology Program “Genistein is a naturally occurring isoflavone that interacts with estrogen receptors and multiple other molecular targets. Human exposure to genistein is predominately through consumption of soy products, including soy-based infant formula and dietary supplements. …..but concerns have also been raised regarding potential adverse effects of genistein, particularly with regard to reproductive toxicity and the induction of potentiation of carcinogenesis due primarily to its weak estrogenic activity. In F(1) C males (continuous genistein exposure from conception through 2 years), a significant positive trend occurred in the incidences of combined adenoma or carcinoma of the pancreatic islets. Conclusions: There was some evidence of carcinogenic activity of genistein in female Sprague-Dawley (SD) rats based on increased incidences of mammary gland adenoma or adenocarcinoma (combined) and pituitary gland neoplasms. There was equivocal evidence of carcinogenic activity of genistein in female SD rats based on marginally increased incidences of pituitary gland neoplasms. Exposure to genistein in was also shown to accelerate the onset of aberrant estrous cycles in female SD rats…. The effects of genistein on estrous cycling and incidences of common hormonally related spontaneous neoplasms of female SD rats are consistent with an estrogenic mechanism of toxicity.”
J. Agric Food Chem 2010 Apr 14;58(7):4529-36 “Absolute bioavailability of isoflavones from soy protein isolate-containing food in female BALB/c mice.” Dept of Food Science and Human Nutrition U of IL. JE Andrade et al, “Soy isoflavones, genistein and daidzein, are widely consumed in soy-based foods and dietary supplements for their putative health benefits; however, evidence for potential adverse effects has been obtained from experimental animals studies. These results show that soy protein isolate (as found in infant formulas) is an efficient isoflavone delivery vehicle capable of providing significant proportions of the total dose into the circulation in the active aglycone form for distribution to receptor-bearing tissues and subsequent pharmacological effects that determine possible health benefits and/or risks.”
Int J Toxicol 2002 Jul-Aug;21(4): 277-85, “Genotoxicity and carcinogenicity studies of soy isoflavones.” National Cancer Institute Bethesda, RR Misra et al. “…..there remains a mechanistic concern associated with the ability of isoflavones (i.e. genistein) to inhibit topoisomerase, possibly leading to DNA strand breaks. Mouse lymphoma cell mutagenesis experiments conducted with and without metabolic activation revealed statistically significant increases in mutation frequency at PTI G 2535 (investigative soy isoflavone drug product), concentrations > or = 0.8 and 12 microg/ml, respectively; such increases were dose related and increases in frequency of both small and large colonies were observed. A statistically significant increase in the frequency of micronucleated polychromatic erythrocytes (evidence of genotoxic exposure) was also seen 24 hours after treatment in male, but not female mice…..The apparent risk/benefit of isoflavone ingestion may ultimately depend on the dose and the developmental timing of exposure.”
Food Chem Toxicol 2006 Jan:44(1):42-55 “Genetic toxicity studies with genistein” Michael McClaim et al, michaelmcclain@msn.com “Genistein is a phytoestrogen that occurs naturally in the diet especially in soybeans and soy-based foods…..concern has been raised of potential adverse effects due to estrogenic and other activities of the isoflavones. In the in vitro mouse lymphoma assay, genistein increased resistant mutants with and without metabolic activation…indicating that genistein acts as a clastogen. This observation is in agreement with published data on the inhibitory action of genistein on topoisomerase II which is known to lead to chromosomal damage with a threshold dose response.”
(Note Soy-Caused Damage to Topoisomerase II Is A Proven Cause of Leukemia)
Soy-Cause of Leukemia:
Biocehm Biophys Res Commun 2010, Aug 13;399(1):66-71 “Genistein induces topoisomerase IIbeta-and proteasome-mediated DNA sequence rearrangements: Implications in Infant Leukemia.” AM Azarova et al, lyuyi@umdnj.edu “Genistein is a bioflavonoid enriched in soy products. However, high levels of maternal soy consumption have been linked to the development of infant leukemia ALL and AML. Together, our results suggest a model in which genistein-induced Top2beta cleavage complexes are processed by proteasome, leading to the exposure of otherwise Top2beta-concealed DNA doubles strand breaks and subsequent chromosome rearrangements, and implicate a major role of Top2beta and proteasome in genistein-induced infant leukemia.”
Soy-Cause of Cancer In Estrogen Sensitive Organs:
Biochemistry 2004, Mar 9; 43(9):2569-77, “Genistein and daidzein induce cell proliferation and their metabolites cause oxidative DNA damage in relation to isoflavone-induced cancer of estrogen-sensitive organs.” M. Murata et al, Department of Environmental and Molecular Medicine. Japan. “These findings suggest that oxidative DNA damage by isoflavone metabolites plays a role in tumor initiation and that cell proliferation by isoflavones via ER- ERE (estrogen receptors- estrogen response element) binding induced tumor promotion and/or progression resulting in cancer of estrogen-sensitive (reproductive) organs.”
Soy-Cause of Adverse Reproductive Effects:
Reprod Toxicol, 2011, Apr;31(3):272-9 “Circulating levels of genistein in the neonate apart from dose and rout, predict future adverse female reproductive outcomes.” Jefferson WN, Williams CJ, NIEHS jeffers1@niehs.nih.gov “Developmental exposure to estrogenic compounds can disrupt sexual differentiation and adult reproductive function in many animals including humans. Phytoestrogens in the diet comprise a significant source of estrogenic exposure to humans, particularly infants who are fed soy-based infant formula. Taken together, the studies clearly demonstrate that environmentally relevant doses of (soy) genistein have significantly negative impacts on ovarian differentiation, estrous cyclicity, and fertility in the rodent model. These models have used various dosing strategies to mimic the phytoestrogen levels in human populations. Additional studies of reproductive function in human populations exposed to high levels of phytoestrogen during development are warranted.”
Bio Reprod 2010, July;83(1):114-21 “Acute and chronic effects of oral genistein administration in neonatal mice” Division of Nutritional Sciences University of IL. MA Cimafranca et al. “Soy-based infant formulas are widely used in the United States and some other countries. These formulas contain high levels of the estrogenic isoflavone genistein, leading to concern that neonatal genistein exposure could cause acute and/or long-term adverse effects on reproductive and other organs. Our objective was to develop a mouse model that more closely mimics the oral genistein exposure and total serum genistein concentrations observed in soy formula-fed infants. At Postnatal Day 5 neonatal genistein treatment caused increased relative uterine weight and down-regulation of progesterone receptor in uterine epithelia. Estrogenic effects of genistein were also seen in the neonatal ovary and thymus, which had an increase in incidence of multioocyte follicles (MOF) and a decrease in thymic weight relative to body weight….The increased incidence of MOFs persisted into adulthood for neonatally treated genistein females, and estrous cycle abnormalities were seen at 6 mo of age….The immediate and long-term effects in this neonatal animal model raises concerns that high serum concentrations of genistein are estrogenic and could potentially impact the development of human infants fed soy formula.”
Mol Nutr Food Res 2007, Jul:51(7):832-44 “Disruption of the developing female reproductive system by phytoestrogens: genistein as an example.” National Institute of Environmental Health Sciences NIEHS. WN Jefferson et al, jeffers1@niehs.nih.gov “Studies in our laboratory have shown that (mice) exposure to genistein causes deleterious effects on the developing female reproductive system. Further, transgenerational effects were observed; female offspring obtained from breeding genistein treated females (25mg/kg)…..Thus, neonatal treatment with genistein at environmentally relevant doses caused adverse consequences on female development which is manifested in adulthood.”
Biology of Reproduction 2005, 73; 798-806 “Adverse effects on female Development and Reproduction in CD-1 Mice Following Neonatal Exposure to the Phytoestrogen Genistein at Environmentally Relevant Doses.” Wendy N. Jefferson et al, National Institute of Environmental Health Sciences jeffers1@niehs.nih.gov “In summary, neonatal treatment with Genistein caused abnormal estrous cycles, altered ovarian function, early reproductive senescence, and subfertility/infertility at environmentally relevant doses.”
Wei Sheng Yan Jiu 2007 Sep:36(5)564-7 “Effects of lactational exposure to soy isoflavones on steroid receptor expression in neonate rat ovaries.” Institute of Nutrition and Food Safety, Chinese Center for Disease Control and Prevention. L Li et al report; “Objective to study the effects of lactational exposure to soy isoflavones on ovary development in neonate rats. Conclusion: Lactational exposure to soy isoflavones could induce adverse effects on ovary development in neonate rats, which mechanisms may at least, particularly involve modification of mRNA transcription for ER and PR.”
Environ Health Prospect 2009 Dec;117(12):1883-9 “Oral exposure to genistein, the glycosylated form of genistein,during neonatal life adversely affects the female reproductive system.” WN Jefferson et al, jeffers1@niehs.nih.gov “Developmental exposure to environmental estrogens is associated with adverse consequences later in life. Exposure to genistin the glycosylated form of the phytoestrogen genistein found in soy products if of concern….High circulating levels of genistin have been measured in the serum of these infants, indicating that genistin is readily absorbed, hydrolyzed and circulated. Results: Oral genistin elicited an estrogenic response in the neonatal uterus….Oral genistin altered ovarian differentiation, delayed vaginal opening, caused abnormal estrous cycles, decreased fertility and delayed parturition.”
Reprod Toxicol 2009 Jul;28(1):52-8 “Impact of genistein on maturation of mouse oocytes, fertilization, and fetal development.” Dept of Bioscience Technology and Center for Nanotechnology, Li Chung and WH Chan whchan@cycu.edu.tw “Genistein a natural isoflavone compound found in soy products, affects diverse cell functions, including proliferation, differentiation and cell death. An earlier study by our group showed that genistein has cytotoxic effects on mouse blastocysts and is associated with defects in their subsequent development in vitro. Genistein induced a significant reduction in the rate of oocyte maturation, fertilization and in vitro embryo development. With the aid of an in vivo mouse model we showed that consumption of drinking water containing genistein led to decreased oocyte maturation and in vitro fertilization, as well as early embryonic developmental injury. Moreover, our findings support a degree of selective inhibition of retinoic acid receptors in blastocysts treated with genistein during oocyte maturation.”
Exp Biol Med 2004, Jan;229(1): 108-17, “Effects of genistein or soy milk during late gestation and lactation on adult uterine organization in the rat.” Dept of Medical and Scientific Services, Triangle Park, NC. CL Hughes et al, Hughes@quintiles.com “In utero and lactational exposure to estrogenic agents has been shown to influence morphological and functional development of reproductive tissues. Thus consumption of dietary (soy) phytoestrogens, such as isoflavones during pregnancy and lactation could influence important periods of development when the fetus and neonate are more sensitive to estrogen exposure. However, soy milk exposure induced a significant increase in progesterone receptor (PR) in the uterine glandular epithelium of the 2-month-old pups. These experiments demonstrate that developmental exposure to dietary isoflavones at levels comparable to the ranges of human exposure modify expression of the estrogen-regulated PR in the uterus of sexually mature rats weeks after exposure ended. Sine the PR is essential for regulating key female reproductive processes, such as uterine proliferation, implantation, and maintenance of pregnancy, its increased expression suggests that soy phytoestrogen exposure during reproductive development may have long-term reproductive (adverse) health consequences.”
NTP CERHR Expert Panel Report on the Reproductive and Developmental Toxicity of Genistein. October 2007. “Conclusions of expert panel: Evidence is sufficient to conclude that genistein produces reproductive/developmental toxicity in the offspring (i.e., F1, F2, F3 of rats at 500 ppm, approximately 35mg/kg/bw/day in males and 44mg/kg bw/day in females) via oral administration ……. The Experimental animal data are assumed relevant to the assessment of human risk.”
The Journal of Clinical Endocrinology & Metabolism, 1999 “Phytoestrogens Alter Adrenocortical Function: Genistein and Daidzein Suppress Glucocorticoid and Stimulate Androgen Production by cultured Adrenal Cortical Cells” Sam Mesiano et al, Dept of Obstetrics , Gynecology and Reproductive Sciences, UC San Francisco robert_jaffe@quickmail.ucsf.edu “Phytoestrogens influence a variety of biological processes. Therefore, consumption of foods containing phytoestrogens may alter adrenocortical function by decreasing cortisol and increasing androgen production.”
J. Urol 2011, May;185(5):1894-8 “Molecular effects of genistein on male urethral development” AE Ross et al Department of Urology, Johns Hopkins School of Medicine “Gestational exposure to genistein contributes to hypospadias by altering pathways of tissue morphogenesis, cell proliferation and cell survival. Gestational exposure to genistein contributes to hypospadias by alerting pathways of tissue morphogenesis, cell proliferation and cell survival. In particular, genes in the…… signaling pathways and those controlled by……..estrogen receptor transcription factors are disrupted.”
Int J Androl 2010, Apr;33 (2):304-16 “Soy, phyto-estrogens and male reproductive function: a review.” CR Cederroth et al, Dept of Genetic Medicine and Development, U of Geneva, Switzerland. “There is growing interest in the possible health threat posed by the effects of endocrine disruptors on reproduction. Soy and soy derived products contain isoflavones that mimic the actions of estrogens and may exert adverse effects on male fertility. Overall there are some indications that phyto-estrogens, alone or in combination with other endocrine disruptors may alter reproductive hormones, spermatogenesis, sperm capacitation and fertility. Further investigation is needed before a firm conclusion can be draw. In the meantime, caution would suggest that perinatal phytoestrogen exposure such as that found in infants feeding on soy-based formula should be avoided.”
Breast Cancer:
Nutr Cancer 2007;58(2): 222-9 “The effects of the phytoestrogens genistein,daidzein and equol on the growth of tamoxifen-resistant T47D/PKC alpha” DA Tonetti et al, Dept. of Biopharmaceutical Sciences, University of Chicago dtonetti@uic.edu “Interestingly, coadministration of tamoxifen with either (soy) daidzein or genistein produced (breast cancer) tumors of greater size than with tamoxifen alone. These findings suggest that simultaneous consumption of isoflavone supplements with tamoxifen may not be safe.”
Toxicology 2011, Nov 18;289(2-3) 67-73 “Genistein induces breast cancer-associated aromatase and stimulates estrogen-dependent tumor cell growth in vitro breast cancer model.” MB Van Dursen et al, Endocrine Toxicology. The Netherlands. M.vanduursen@uu.nl “These data suggest that soy-based supplements might affect the efficacy of breast cancer treatment with aromatase inhibitors. Considering the high number of breast cancer patients using soy supplements to treat menopausal symptoms, the increasing risk for adverse interactions with breast cancer treatment is of major concern and should be considered with care.”
Carcinogenesis 2008, Nove;29(11):2126-8 “Dietary genistein negates the inhibitory effect of letrozole on growth of aromatase-expressing estrogen dependent human breast cancer cells in vivo” YH Ju et al, Dept of Food Science and Human Nutrition, Urbana Il “Genistein, a soy isoflavone stimulates growth of estrogen-dependent human tumor cells….. Caution is warranted for consumption of dietary genistein by postmenopausal women with estrogen-depended breast cancer taking letrozole (aromatase inhibitor) treatment.”
Soy-Cause of Uterine Cancer:
Cancer Res 2001 Jun1;61(11):4325-8 “Uterine adenocarcinoma in mice treated neonatally with genistein” National Institute of Environmental Health Sciences. NIEHS. Newbold RR, newbold1@niehs.nih.gov “The developing fetus is uniquely sensitive to perturbation with estrogenic chemicals. Because phytoestrogen use in nutritional and pharmaceutical applications for infants and children is increasing we investigated the carcinogenic potential of genistein, a naturally occurring plant estrogen in soy. These data suggest that genistein is carcinogenic if exposure occurs during critical periods of differentiation. Thus the use of soy-based infant formulas in the absence of medical necessity and the marketing of soy products designed to appeal to children should be closely examined.”
Soy Cause of Thymic Damage and Immune Abnormalities
PNAS May 28, 2002, 99(11): 7616-21 “The phytoestrogen genistein induces thymic and immune changes: A human health concern?” Yellayi Srikanth et al, “These results raise the possibility that serum genistein concentrations found in soy-fed infants may be capable of producing thymic and immune abnormalities as suggested by previous reports of immune impairments in soy-fed human infants.”
Soy-Cause of Migraine Headaches:
Neurology 2002, Oct 2; Vol 59(8):1289 “New onset migraine associated with use of soy isoflavone supplements” Peter Engel Geriatric and Extended Care Albany, NY Peter.Engel@med.va.gov “This report describes the first attack of migraine with visual aura in 57-year old man who had introduced soy isoflavone supplements into his diet 9 months earlier. Symptoms disappeared after a reduction in the dose of these phytoestrogen compounds.”
1998 NIEHS Letter of Opposition: To Archer Daniels Midland. Regarding: application for GRAS status of Soy.
NIEHS scientist Dr. Daniel M. Sheehan “Dear (FDA) Dr. Linda Kahl, We oppose GRAS status of soy because that is abundant evidence that some of the isoflavones, including genistein and equol are toxicants. This is true for a number of species, including humans. Additionally, the adverse effects in humans occur in several tissues and, apparently, by several mechanisms. Genistein is clearly estrogenic….and induces estrogenic responses in developing and adult animals and in adult humans. ….equol is estrogenic and acts as an estrogenic endocrine disruptor during development. Thus, consumption of (soy) isoflavones during pregnancy in humans could be a risk factor for abnormal brain and reproductive tract development. Additionally, isoflavones are inhibitors of the thyroid peroxidase which makes T3 and T4. Inhibition can be expected to generate thyroid abnormalities, including goiter and autoimmune thyroiditis. There exists a significant body of animal data that demonstrates goitrogenic and even carcinogenic effects of soy products….The thyroid findings in infants receiving soy formula re a result of serum levels of isoflavones that are about 5 times higher than in women receiving soy supplements who show menstrual cycle disturbances, including increased estradiol level in the follicular phase. As all estrogens which have been studied carefully in human populations are two-edged swords in humans…..it is likely that the same characteristic is shared by the isoflavones. The animal data is also consistent with adverse effects in humans. Subsequently, this same group showed a significant does-dependent risk for development of vascular dementia and brain atrophy from consumption of tofu, a soy product rich in isoflavones. Given that estrogens are important for maintenance of brain function in women: that the male brain contains aromatase, the enzyme that converts testosterone to estradiol: and that isoflavones inhibit this enzymatic activity, there is a mechanistic basis for the human findings. I am unconvinced that the long history of apparent safe use of soy products can provide confidence that they are indeed without risk. Taken together, the findings presented here are self-consistent and demonstrate that genistein and other isoflavones have adverse effects in a variety of species, including humans. The addition of isoflavones to foods needs to be considered just as would the addition of any estrogen to foods, which is a bad idea.”
Soy Cause Allergies:
Crit Rev Food Sci Nutr 2007; 47(2):127-43 “Allergenicity of soybean….” L. L’Hocine and JL Bove. Food Research and Development Center Agriculture and Agri-Food Canada “Soybean is considered one of the “big eight” foods that are believed to be responsible for 90% of all allergenic reactions. Soy allergy is of particular importance, because soybeans are widely used in processed foods and therefore, represent a particularly insidious source of hidden allergens.”
Purported Soy Benefits: Inconsistent and Inadequate:
American Society for Nutrition 2008, 138:1244S-49S “Health Effects of Soy Protein and Isoflavones in Humans” Chao Wu Xiao, Nutrition Research Division, Department of Cellular and Molecular Medicine Canada chaowu_xiao@hc-sc.gc.ca “Impacts of soy products on thyroid and reproductive functions as well as on certain types of carcinogenesis require further study in this context. Overall, existing data are inconsistent or inadequate in supporting most of the suggested health benefits of consuming soy protein or ISF (isoflavones).”
The FDA Continues to Confirm Soy Endocrine Disruptor Toxicity, While Avoiding Public Disclosure While Concluding: “Studies Are In Progress”:
Neurotoxicology 2000 Feb-Apr;21(1-2):250 US Food and Drug Administration "Developmental neurotoxicity of endocrine disruptors focus on estrogens." Schwetz BA. "Genistein, a naturally occurring estrogen mimic found in soy beans and soy products....are chemicals on which multigenerational studies are in progress. These studies will compare toxicity in neural, immune, and reproductive systems and in some cases will evaluate potential carcinogenicity."
Note- It is FDA acknowledged that for a few prior decades soy phyto-estrogens are proven as active endocrine disruptors, and that endocrine disruptors are overwhelmingly confirmed in the cause of several severe and potentially fatal disorders and diseases. FDA continues to state over and over again that they are investigating soy endocrine disruptor toxicity, while without public disclosure. It is decades past due that the American public is equally informed about the several hundred published adverse health studies that have repeatedly proven soy as a toxic plant endocrine disruptor. The truth is that ongoing studies repeatedly confirm there are in fact multiple toxic soy components, (inhibition of essential enzymes, phytic acid, heavy metals, anti-nutrients) capable of causing extensive adverse body and brain effects. Interestingly, the FDA tends to focus on desperately seeking soy pharmaceutical-like benefits, while ignoring resulting adverse soy effects. Soy remains an undisclosed and undocumented FDA experiment that especially proves toxic to fetus, infants, and children exposed. Fear that increasing soy phyto-toxic studies will continue, indefinitely, without public disclosure…....FDA approved.
TO BE CONTINUED: More Published Studies Are COMING SOON! How Many Toxic Soy Studies Does It Take For USA FDA To Responsibly Take Action? With More Than 700 Studies Reporting Soy Phyto-Toxicity It Is Clear That The FDA Is Protecting This Powerful Billion Dollar Industry, Furthest From Their Promised Duty To Protect Public Health.
Gail Elbek
gaelbek@yahoo.com
